Logo do repositório
 
Publicação

Beneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer’s disease

2018Artigo científico Acesso aberto
Ver registo simples
dc.contributor.authorFaivre, Emilie
dc.contributor.authorCoelho, Joana E
dc.contributor.authorZornbach, Katja
dc.contributor.authorMalik, Enas
dc.contributor.authorBaqi, Younis
dc.contributor.authorSchneider, Marion
dc.contributor.authorCellai, Lucrezia
dc.contributor.authorCarvalho, Kevin
dc.contributor.authorSebda, Shéhérazade
dc.contributor.authorFigeac, Martin
dc.contributor.authorEddarkaoui, Sabiha
dc.contributor.authorCaillierez, Raphaëlle
dc.contributor.authorChern, Yijuang
dc.contributor.authorHeneka, Michael
dc.contributor.authorSergeant, Nicolas
dc.contributor.authorMüller, Christa E.
dc.contributor.authorHalle, Annett
dc.contributor.authorBuée, Luc
dc.contributor.authorLopes, Luisa V.
dc.contributor.authorBlum, David
dc.date.accessioned2022-12-14T13:43:25Z
dc.date.available2022-12-14T13:43:25Z
dc.date.issued2018
dc.descriptionCopyright © 2018 Faivre, Coelho, Zornbach, Malik, Baqi, Schneider, Cellai, Carvalho, Sebda, Figeac, Eddarkaoui, Caillierez, Chern, Heneka, Sergeant, Müller, Halle, Buée, Lopes and Blum. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.pt_PT
dc.description.abstractConsumption of caffeine, a non-selective adenosine A2A receptor (A2AR) antagonist, reduces the risk of developing Alzheimer's disease (AD) and mitigates both amyloid and Tau lesions in transgenic mouse models of the disease. While short-term treatment with A2AR antagonists have been shown to alleviate cognitive deficits in mouse models of amyloidogenesis, impact of a chronic and long-term treatment on the development of amyloid burden, associated neuroinflammation and memory deficits has never been assessed. In the present study, we have evaluated the effect of a 6-month treatment of APPsw/PS1dE9 mice with the potent and selective A2AR antagonist MSX-3 from 3 to 9-10 months of age. At completion of the treatment, we found that the MSX-3 treatment prevented the development of memory deficits in APP/PS1dE9 mice, without significantly altering hippocampal and cortical gene expressions. Interestingly, MSX-3 treatment led to a significant decrease of Aβ1-42 levels in the cortex of APP/PS1dE9 animals, while Aβ1-40 increased, thereby strongly affecting the Aβ1-42/Aβ1-40 ratio. Together, these data support the idea that A2AR blockade is of therapeutic value for AD.pt_PT
dc.description.sponsorshipThis work was supported by a cross-border grant from LECMA/Alzheimer Forschung Initiative/Vaincre Alzheimer (to DB and CM). We hereby thank Frédéric Leprêtre for submitting transcriptomics data to GEO. EF and KC are supported by Université de Lille, LC was supported by Italian Society of Pharmacology and LabEx DISTALZ.pt_PT
dc.description.versioninfo:eu-repo/semantics/publishedVersionpt_PT
dc.identifier.citationFront Mol Neurosci. 2018 Jul 12;11:235pt_PT
dc.identifier.doi10.3389/fnmol.2018.00235pt_PT
dc.identifier.issn1662-5099
dc.identifier.urihttp://hdl.handle.net/10451/55391
dc.language.isoengpt_PT
dc.peerreviewedyespt_PT
dc.publisherFrontierspt_PT
dc.relation.publisherversionhttps://www.frontiersin.org/journals/molecular-neurosciencept_PT
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/pt_PT
dc.subjectA2Apt_PT
dc.subjectAlzheimer’s diseasept_PT
dc.subjectAdenosine receptorpt_PT
dc.subjectAmyloidpt_PT
dc.subjectMemorypt_PT
dc.titleBeneficial effect of a selective adenosine A2A receptor antagonist in the APPswe/PS1dE9 mouse model of Alzheimer’s diseasept_PT
dc.typejournal article
dspace.entity.typePublication
oaire.citation.titleFrontiers in Molecular Neurosciencept_PT
oaire.citation.volume11pt_PT
person.familyNameCoelho
person.familyNameLopes
person.givenNameJoana
person.givenNameLuisa
person.identifier149432
person.identifier.ciencia-idB310-839B-564D
person.identifier.ciencia-id4817-7194-C024
person.identifier.orcid0000-0002-3964-6197
person.identifier.orcid0000-0001-8367-3005
person.identifier.scopus-author-id7101840699
person.identifier.scopus-author-id7102509159
rcaap.rightsopenAccesspt_PT
rcaap.typearticlept_PT
relation.isAuthorOfPublication1301afd3-8056-4d54-983c-0bec935b2d75
relation.isAuthorOfPublicationdfc15976-b186-45d1-be1c-4592b336edb1
relation.isAuthorOfPublication.latestForDiscoverydfc15976-b186-45d1-be1c-4592b336edb1

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
Beneficial_effect.pdf
Tamanho:
2.81 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
1.2 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

IMM - Artigos em Revistas Internacionais
FM - Artigos em Revistas Internacionais